[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biomarkers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biomarkers":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,50,82,109,138,176,208,249,280,306,332,356,386,418,443,469,494,516,549,579,606,628,655,683,715],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644961","interest-of-the-negative-predictive-value-of-integrons-in-the-reduction-of-large-broad-spectrum-antibiotics-consumption-for-urinary-tract-infections-100644961",false,"NCT07675018","INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS","INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS: a Randomized Trial","INVICTUS","Inclusion Criteria:\n\n* Age ≥ 18 years old; Hospitalized or admitted to the Emergency department;\n* Diagnosis of non-severe (qSOFA \\\u003C 2) urinary tract infection coupled with fever ≥ 38°C or \\\u003C 36°C\n* Presence of bacteria in the fresh urine sample and\u002For GNB on the Gram stain\n* Empirical parenteral antibiotic therapy required; Hospitalization required;\n* Former documentation of a 3GC-resistant GNB on a microbiological sample in the previous six months\n* Informed consent of the patient or their representative\n\nExclusion Criteria:\n\n* Pregnant and\u002For breastfeeding\n* Neutropenia (absolute neutrophil count \\\u003C 500 \u002F mm3)\n* Severe UTI with sepsis (qSOFA ≥ 2) or septic shock\n* Urinary derivation required (ureteral catheter\u002Fper-cutaneous nephrostomy) except for simple urinary catheterization\n* Known allergy to β-lactams\n* Patients with a former documentation with carbapenemase-producing Enterobacterales in the last 6 months\n* Ongoing antibiotic treatment with 3GC, piperacillin-tazobactam or carbapenem\n* Not affiliated to Social Security","ALL","18 Years",{"count":21,"type":22},204,"ESTIMATED","INTERVENTIONAL",[25],"NA","Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections. Integrons play a major role in the dissemination of antibiotic resistance among GNB. In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA\\\u003C2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.",[28,29,30,31],"Drug Resistance, Microbial","Biomarkers","Urinary Tract Infections (UTI's)","Antibacterial Agents",[33,34,35,36],"Integron","Antimicrobial Stewardship","Antimicrobial Resistance","Urinary Tract Infections","NOT_YET_RECRUITING","2026-06-29",{"date":40,"type":41},"2026-07-01","ACTUAL",{"date":43,"type":22},"2026-09-15",{"date":45,"type":22},"2028-09-21",{"name":47,"class":48},"University Hospital, Limoges","OTHER",7,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100638674","cerebral-small-vessel-disease-progression-dependent-on-stroke-type-100638674","NCT07611136","Cerebral Small Vessel Disease Progression Dependent on Stroke Type","Biomarker-based Assessment of Cerebral Small Vessel Disease Progression After Lacunar and Territorial Stroke - a Prospective Cohort Study","ZMA_BIO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Evidence of cerebral small vessel disease on brain MRI, defined as white matter hyperintensities (Fazekas grade 1-3)\n* Assignment to one of the following study groups based on MRI findings:\n* cerebral small vessel disease without evidence of an acute ischemic stroke\n* cerebral small vessel disease with acute lacunar ischemic stroke\n* cerebral small vessel disease with acute territorial ischemic stroke\n* Ability to provide written informed consent\n* Sufficient German language skills to understand study procedures and assessments\n\nExclusion Criteria:\n\n* Alternative plausible causes of white matter hyperintensities other than cerebral small vessel disease (e.g. inflammatory central nervous system disorders, leukodystrophies, brain tumors)\n* Known neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, other dementias)\n* Acute or recent traumatic brain injury\n* Contraindications to magnetic resonance imaging\n* Pregnancy or breastfeeding\n* Life expectancy of less than one year\n* Inability to comply with study procedures or follow-up visits",{"count":59,"type":22},180,"1 Year","OBSERVATIONAL","The goal of this prospective, observational study is to understand if cerebral small vessel disease (CSVD) has different velocities and patterns of temporal development, dependent on a concurrent ischemic stroke. It focusses on adult patients with known or newly diagnosed CSVD on magnetic resonance imaging. The study will evaluate if blood based, in parts central nervous system specific protein markers, so called biomarkers, have an additional value reflecting the course of CSVD as defined per MRI assessments. Further patient-relevant endpoints include neuropsychological abilities, neurological functional outcomes, quality of life assessments, stroke recurrence risk.",[64,65,66,29],"Cerebral Small Vessel Disease","Stroke","Stroke Recurrence",[68,69,70],"cerebral small vessel disease","biomarkers","magnetic resonance imaging","RECRUITING","2026-05-20",{"date":74,"type":41},"2026-05-28",{"date":76,"type":41},"2026-03-26",{"date":78,"type":22},"2028-04-01",{"name":80,"class":48},"Johannes Dorst",1,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":99,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":81},"100638614","the-effects-of-high-intensity-interval-training-on-gait-balance-and-cognitive-functions-in-individuals-with-multiple-sclerosis-100638614","NCT07578740","The Effects of High-Intensity Interval Training on Gait, Balance, and Cognitive Functions in Individuals With Multiple Sclerosis","Investigating the Effects of High-Intensity Interval Training on Gait, Balance, and Cognition in Individuals With Multiple Sclerosis","HIIT-MS","Inclusion Criteria:\n\n* Diagnosed with Multiple Sclerosis by a neurologist (Hacettepe University Hospitals, Neurology Outpatient Clinic)\n* Age 18 years and older\n* EDSS score between 0 and 4\n* Score of 24 or above on the Standardized Mini Mental State Examination\n* No relapse in the past 3 months\n* Medically stable for at least 6 months\n\nExclusion Criteria:\n\n• Any additional cardiopulmonary, neurological, or systemic disease other than MS",{"count":5,"type":22},[25],"This study aims to comparatively investigate the effects of low-volume High-Intensity Interval Training (HIIT) versus Moderate-Intensity Continuous Training (MICT) on gait, balance, cognitive functions, and neurovascular biomarkers (BDNF, VEGF) in individuals with Multiple Sclerosis (MS). This randomized controlled trial will be conducted at Hacettepe University, Faculty of Physical Therapy and Rehabilitation.",[94,95,96,97,98,29],"Multiple Sclerosis","High-intensity Interval Training","Gait","Balance","Cognition",[100],"Multiple Sclerosis, High-Intensity Interval Training, HIIT, Gait, Balance, Cognition, BDNF, VEGF, Randomized Controlled Trial","2026-05-18",{"date":72,"type":41},{"date":104,"type":22},"2026-07",{"date":106,"type":22},"2028-06",{"name":108,"class":48},"Hacettepe University",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":126,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":81},"100500045","epigenetic-biomarkers-in-the-saliva-for-the-diagnosis-of-squamous-cells-carcinoma-of-the-oral-cavity-100500045","NCT05791149","Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity","EPSACO","Inclusion Criteria:\n\n* Patient group:\n* Patients from the maxillofacial surgery department treated for a histologically confirmed squamous cell carcinoma of the oral cavity\n* Patients whose first-line treatment decision at the multidisciplinary meeting in the service of Maxillofacial Surgery is surgery\n* Patients who have not yet been treated surgically or by neoadjuvant treatment\n* Patients over 18 years old\n* Patients who have provided free and informed consent in writing\n* Patients benefiting from a social security scheme\n\nControl group:\n\n* Patients in the maxillofacial surgery department not covered for head and neck cancer\n* Patients over 18 years old\n* Patients who have provided free and informed consent in writing\n* Patients benefiting from a social security scheme\n* Control group homogeneous with the patient group according to age, sex, tobacco and alcohol consumption\n\nExclusion Criteria:\n\n* Patients with other types of cancer\n* Patients under the age of 18\n* Pregnant or breastfeeding women\n* Patients under guardianship, curators, legal protection or deprived of liberty",{"count":117,"type":22},60,[25],"Head and neck squamous cell carcinoma (HNSCC) are malignant tumors originating from the epithelial mucosa of the upper aerodigestive tract. The oral cavity is the most frequent location of HNSCC (oral squamous cell carcinoma: OSCC). Tobacco use and alcohol consumption are the greatest risk factors. The Hauts de France region has one of the highest incidence rates of OSCC. The overall survival of patients with OSCC remains low, with a 5-year overall survival rate of around 60%. In addition to the oncological prognosis, OSCCs and their treatment have a significant impact on the quality of life of patients. An early diagnosis of OSCC is recommended, but it remains difficult. It can be for example challenging to diagnose OSCC in a context of oral premalignant lesions. Identifying objective biomarkers of malignancy would be an advantage and would allow better progress in the field of precision medicine and surgery for these tumors.\n\nThe investigators propose to establish the diagnostic use of an optimized DNA methylation profile detected in the saliva of OSCC patients by comparing these epigenetic marks before and after tumor resection.\n\nThe investigators will construct a consolidated signature of 4 genes whose DNA is subject to methylation and gene expression is restricted to cancer cells, by crossing TCGA analysis with single-cell analysis (single-cell RNA sequencing).\n\nThe investigators propose to analyse DNA methylation of the corresponding genes in the saliva of n=30 OSCC patients recruited for primary surgical resection in the Department of Maxillofacial Surgery vs controls. In addition, the investigators will examine the methylation profiles before \u002F after complete excisional surgery of OSCC. This pilot study will aim to validate the analysis of DNA methylation markers in saliva of OSCC, with the aim of improving the diagnostic precision of OSCC and, secondly, to compare these markers before and after treatment by primary surgery.",[121,122,29,123,124,125],"Oral Squamous Cell Carcinoma","Maxillo-facial Surgery","Saliva","DNA Methylation","Epigenetics",[121,127,29,123,124,128],"Maxillo-facial surgery","epigenetics","2026-05-12",{"date":131,"type":41},"2026-05-13",{"date":133,"type":41},"2022-03-03",{"date":135,"type":22},"2027-10",{"name":137,"class":48},"Centre Hospitalier Universitaire, Amiens",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":146,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":147,"targetDuration":149,"studyType":61,"phases":4,"briefSummary":150,"conditions":151,"keywords":158,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":81},"100637404","ai-assisted-ct-for-risk-stratification-in-coronary-artery-disease-action-100637404","NCT07577609","AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)","Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes","ACTION","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Undergoing clinically indicated cardiac CT\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* History of malignancy\n* Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)\n* Contraindications to iodinated contrast agents or CT imaging",true,{"count":148,"type":22},10000,"5 Years","The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.\n\nThe main questions it aims to answer are:\n\n* Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?\n* How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.\n\nParticipants will:\n\n* Provide informed consent and medical history\u002Fdemographic information\n* Undergo blood sampling for cardiovascular and metabolic biomarkers\n* Have a resting ECG performed\n* Complete a detailed lifestyle and health questionnaire\n* Receive a non-invasive cardiac CT scan interpreted by an expert\n* Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality\n* Be referred for further clinical evaluation if clinically indicated ",[152,153,29,154,155,156,157],"Coronary Artery Disease (CAD)","Computed Tomography Angiography","AI (Artificial Intelligence)","Lipoprotein(a)","Atheroscleroses, Coronary","Myocardial Ischemia",[159,160,161,162,163,164,165,166],"AI-assisted cardiac CT","Coronary CT angiography (CCTA)","Cardiovascular risk stratification","Coronary plaque characterization","High-risk plaque","Machine learning","CT-FFR (fractional flow reserve)","Coronary calcium scoring","2026-05-05",{"date":169,"type":41},"2026-05-11",{"date":171,"type":41},"2022-12-21",{"date":173,"type":22},"2032-12-21",{"name":175,"class":48},"University of Galway",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":146,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":184,"targetDuration":186,"studyType":61,"phases":4,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":81},"100639408","russ-age-creating-of-a-biological-age-calculator-and-study-of-aging-phenotypes-in-the-russian-population-100639408","NCT07574359","RUSS-AGE: Creating of a Biological Age Calculator and Study of Aging Phenotypes in the Russian Population","RUSS-AGE, CREATING OF A BIOLOGICAL AGE CALCULATOR AND STUDY OF AGING PHENOTYPES IN THE RUSSIAN POPULATION","RUSS-AGE","Inclusion Criteria: Signing the informed consent form to participate in the study.\n\nParticipant's age was 18 years or older at the time of inclusion in the study.\n\n\\-\n\nExclusion Criteria:\n\n1. Refusal to participate in the study or to provide informed consent.\n2. History or medical records indicating the presence of infectious diseases (Hepatitis C, Hepatitis B, including HBsAg carrier status, HIV infection).\n3. Presence of an acute illness\u002Fcondition, exacerbation of a chronic disease, or surgical intervention within the last month prior to study inclusion.\n4. Lack of remission from an oncological disease or ongoing anti-tumor therapy initiated less than three years prior to study inclusion.\n5. Severe cognitive or sensory impairments and mental disorders that, in the investigator's opinion, preclude adequate communication with the subject.\n6. Severe forms of chronic non-communicable diseases: life-threatening cardiac arrhythmias, chronic heart failure NYHA Class III-IV, left ventricular ejection fraction \\\u003C40%, ischemic heart disease CCS Class III-IV, chronic kidney disease Stages 4-5, type 1 diabetes mellitus, type 2 diabetes mellitus with terminal stages of complications, systemic connective tissue diseases, chronic obstructive pulmonary disease with respiratory failure of Grade 1 or higher, bronchial asthma requiring glucocorticosteroid therapy, osteoarthritis Kellgren-Lawrence Grade IV, body mass index (BMI) ≥40 kg\u002Fm², as well as documented history of myocardial infarction (MI) or acute cerebrovascular accident (stroke).\n7. Pregnancy or lactation (breastfeeding).\n8. Any other factors that, in the investigator's opinion, may preclude the participant's inclusion in the study.\n\n   Additional exclusion criteria for participants undergoing stool sample collection:\n9. Use of systemic antibiotics for 3 or more days within the 3 months prior to the study start.\n10. Any invasive procedures on the large intestine within the last 3 weeks prior to the study start.",{"count":185,"type":22},3500,"2 Years","This is a multi-center, cross-sectional, observational study aimed at developing biological age calculators specifically for the Russian population investigating various aging phenotypes.\n\nAging is a complex process that varies greatly between individuals, meaning that chronological age does not always reflect one's biological health status. The primary goal of this study is to identify and analyze a comprehensive set of markers (including socioeconomic factors, lifestyle, physical parameters, cognitive function, and laboratory biomarkers) that best reflect the aging process. Using this data, researchers will create a mathematical model to estimate a person's \"biological age.\"\n\nThe study plans to enroll at least 3,500 male and female volunteers aged 18 years and older from across Russia. Participants will be divided into 5-year age groups (e.g., 18-24, 25-29, up to 90+ years) to ensure broad representation.\n\nParticipation involves a single visit to a clinical center. During this visit, participants will undergo:\n\nInterview and questionnaires (assessing health history, lifestyle, socioeconomic status, diet, sleep, and quality of life).\n\nPhysical examination and anthropometric measurements (height, weight, blood pressure, grip strength).\n\nFunctional and cognitive tests (e.g., walking speed, balance tests, memory and attention tasks tailored to age).\n\nCollection of biomaterials: blood (50 ml), urine, and stool samples for extensive laboratory analysis, including routine tests and specialized aging biomarkers. Part of the biomaterials will be biobanked for future scientific research.\n\nInstrumental examinations for a subset of participants: Depending on the center's capabilities and the study protocol, some participants may also undergo additional assessments such as densitometry (bone density scan), bioimpedance analysis (body composition), and brain MRI.\n\nThe results are expected to lead to the creation of a validated biological age calculator for the Russian population. This tool could help identify targets for interventions to promote healthy aging and, in the future, potentially predict the risk of developing age-related chronic diseases.",[189,29],"Healthy Aging",[191,192,193,194,195,196,197,198],"biological age","aging biomarkers","aging clock","biological age calculator","phenotypic age","aging phenotype","healthy aging","machine learning in aging","2026-05-04",{"date":201,"type":41},"2026-05-07",{"date":203,"type":41},"2023-01-12",{"date":205,"type":22},"2030-09",{"name":207,"class":48},"Pirogov Russian National Research Medical University",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":146,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":216,"targetDuration":149,"studyType":61,"phases":4,"briefSummary":218,"conditions":219,"keywords":226,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":244,"leadSponsor":246,"locationsCount":4},"100636173","project-phoenix-molecular-signatures-of-burn-pit-exposure-100636173","NCT07562243","Project PHOENIX: Molecular Signatures of Burn Pit Exposure","Molecular, Genomic, Cellular, and Functional Characterization of Blood Specimens From Former U.S. Service Members With Prior Burn Pit Exposure","PHOENIX","Inclusion Criteria:\n\n* Age 18 years or older at the time of consent\n* Former or current U.S. Service Member, including Active Duty, Reserve, National Guard, or Veteran status\n* For exposed cohort: prior deployment to a location with known burn pit operations, based on participant report and available confirmation when feasible\n* For control cohort: no known deployment to burn pit locations\n* Able and willing to provide informed consent and HIPAA authorization\n* Willing to complete study questionnaires and donate venous blood sample\n* Able to complete study procedures in English or with approved translation support\n* Available for one baseline visit and optional future re-contact, if applicable\n\nExclusion Criteria:\n\n* Active serious illness or infection that, in the investigator's judgment, would compromise participation or specimen integrity\n* Receipt of systemic chemotherapy, immunotherapy, or radiation therapy within the past 6 months\n* High-dose systemic immunosuppression, defined as more than 20 mg prednisone equivalent daily for more than 14 days within the past 3 months\n* Pregnant or currently breast-feeding\n* Hemoglobin less than 10 g\u002FdL, known bleeding disorder, or platelet count less than 100 × 10\\^9\u002FL, if known\n* Severe psychiatric illness or other condition that impairs ability to provide informed consent\n* Prisoner or institutionalized individual\n* Prior participation in this or a related Project PHOENIX protocol\n* Any other condition that, in the investigator's judgment, may increase risk or interfere with study conduct or data integrity",{"count":217,"type":22},1000,"Project PHOENIX is an observational clinical research study designed to characterize molecular, genomic, cellular, and functional features in blood specimens from former U.S. Service Members with prior burn pit exposure and from matched unexposed controls. Participants will complete screening, informed consent, health and exposure questionnaires, and a one-time blood collection. Blood-derived specimens may undergo genomic, epigenomic, transcriptomic, proteomic, metabolomic, immunophenotyping, and cellular functional analyses. Participants may also agree to optional future re-contact for health updates and possible repeat blood collection. The goal is to identify biologic signatures associated with prior deployment-related burn pit exposure and to support future biomarker discovery and translational research in veteran health.",[220,221,222,223,29,224,225],"Burn Pit Exposure","Airborne Hazard Exposure","Veteran Health","Deployment-Related Toxic Exposure","Immune Dysfunction","Respiratory Symptoms",[227,228,229,230,231,232,233,234,235,236,237,238,239],"Burn pit","Airborne hazards","Veterans","Deployment exposure","Multi-omics","PBMC","Biomarker discovery","Transcriptomics","Epigenomics","Proteomics","Metabolomics","Toxic exposure","Military service","2026-04-27",{"date":242,"type":41},"2026-05-01",{"date":242,"type":22},{"date":245,"type":22},"2031-12-31",{"name":247,"class":248},"Creative Medical Technology Holdings Inc","INDUSTRY",{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":146,"sex":256,"minAge":19,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":260,"conditions":261,"keywords":265,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":81},"100631759","biomarkers-in-apical-periodontitis-100631759","NCT07504861","Biomarkers in Apical Periodontitis","Effects of Different Irrigation Activation Techniques on Pro-inflammatory Cytokine and Proteolytic Enzyme Levels in Teeth With Chronic Apical Periodontitis","Inclusion Criteria:\n\n* Male patients aged 18-35 years.\n* Presence of chronic apical periodontitis in maxillary or mandibular incisors, canines, or single-rooted\u002Fsingle-channeled premolars.\n* History of root canal treatment performed at least 4 years ago.\n* Presence of a periapical lesion smaller than 1 cm.\n* Periapical Index (PAI) score of 3 or 4 according to Orstavik classification.\n\nExclusion Criteria:\n\n* Need for antibiotic prophylaxis\n* Diabetes\n* Hematological disorders\n* Use of antibiotics or anti-inflammatory drugs within the last month.\n* Excessive plaque and tartar\n* Gum redness or bleeding\n* Severe gingivitis\n* Widespread periodontitis\n* Periodontal pocket depths exceeding 3 mm.\n* Presence of sinus fistula (bleeding).\n* Presence of internal or external root resorption.\n* Pain on palpation of teeth\n* Swelling\n* Pregnancy during treatment.","MALE","35 Years",{"count":259,"type":22},66,"Aim: To evaluate the effects of three different irrigation activation techniques-conventional syringe irrigation (CSI), ultrasonic irrigation (UI), and SWEEPS (Shock Wave Enhanced Emission Photoacoustic Streaming)-on the levels of proinflammatory cytokines (Tumor Necrosis Factor Alpha (TNF-α), interleukin-1beta (IL-1β)) and proteolytic enzymes matrix metalloproteinase-9 (MMP-9) in teeth with chronic apical periodontitis.\n\nMethodology: Sixty-six male patients (aged 18-35) with single-rooted teeth, previous root canal treatment (at least 4 years ago), and periapical lesions (\\\u003C1 cm, PAI score 3 or 4) were included. Sample size was determined by G\\*Power (Power=0.90, α=0.05). Following local anesthesia and rubber dam isolation, endodontic access was performed under a dental operating microscope. After removing old filling material and completing root canal preparation with Reciproc R25\u002FR50 files, patients were randomly assigned into three groups (n=22 each): (1) CSI (30G needle), (2) UI (EMS miniPiezon), and (3) SWEEPS (Er:YAG laser, 2940 nm). Periapical exudate samples were collected using sterile paper points (2 mm beyond the apex for 60s) at the first visit (pre-treatment) and the second visit (one week post-medication with calcium hydroxide). Samples were analyzed via ELISA for TNF-α, IL-1β, and MMP-9 levels.\n\nStatistical Analysis: Data were analyzed using IBM SPSS 20. Percent changes in biomarker levels were evaluated using the Kruskal-Wallis test for inter-group comparisons and the Wilcoxon test for intra-group (pre- vs. post-treatment) comparisons. Linear regression was used to identify effective factors (group, age, gender, tooth type). Significance was set at (p \\\u003C 0.05).\n\nKeywords: Apical periodontitis, SWEEPS, Ultrasonic activation, Cytokines, MMP-9, Endodontics.",[262,263,29,264],"Apical Periodontitis","Retreatment","Cytokine",[266,267,268,269,270,271],"Apical periodontitis","SWEEPS","Ultrasonic activation","Cytokines","MMP-9","Endodontics",{"date":273,"type":41},"2026-04-01",{"date":275,"type":22},"2026-03-30",{"date":277,"type":22},"2026-09-28",{"name":279,"class":48},"Kırıkkale University",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":289,"conditions":290,"keywords":293,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":81},"100593924","pleural-effusion-biomarkers-in-lung-adenocarcinoma-patients-100593924","NCT07012759","Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients","Novel Pleural Effusion Biomarkers Screening and Evaluation in Lung Adenocarcinoma Patients","Inclusion Criteria:\n\n* Patients requiring thoracentesis for pleural effusion drainage as determined by a physician based on clinical need.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients under the age of 18.\n* Patients with malignancies other than lung adenocarcinoma.",{"count":288,"type":22},100,"This project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as potential diagnostic genes for lung adenocarcinoma.",[29,291,292],"Lung Adenocarcinoma","Pleural Effusion",[294,69,295,296],"Pleural effusion","lung cancer","clinical diagnosis","2026-03-04",{"date":299,"type":41},"2026-03-05",{"date":301,"type":41},"2025-06-10",{"date":303,"type":22},"2026-12-31",{"name":305,"class":48},"Fu Jen Catholic University",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":331},"100306395","thrombus-composition-in-ischemic-stroke-analysis-of-the-correlation-with-plasma-biomarkers-efficacy-of-treatment-etiology-and-prognosis-100306395","NCT03268668","Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis","COMPO-CLOT","Inclusion Criteria:\n\n* Patients aged 18 years and older\n* Presenting with cerebral infarction following arterial occlusion\n* Treated for mechanical thrombectomy (whether performed or not)\n* Free, informed, and express consent of the patient or their relatives (emergency inclusion procedure)\n* For retrospective patients: thrombus already collected (according to the center's usual practice or for another research project).\n\nExclusion Criteria:\n\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman",{"count":314,"type":22},1200,"The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes. This treatment option also opens up a new field of research, making possible the analysis of the clot responsible for intracranial occlusion. Indeed, in about 30% of the cases, the thrombectomy procedure makes it possible to retrieve either partially or completely the clot. Previous studies have analyzed the correlation between the composition of the thrombus and the etiology of stroke. Their discordant results do not yet make it possible to distinguish a particular profile of thrombus according to etiology. Other studies have shown a correlation between the proportion of red blood cells in a thrombus and the likelihood that it is visible in MRI or cerebral scanning. More recently, one study has demonstrated a correlation between the presence of lymphocytes in the thrombus and an atheromatous etiology.\n\nThe main limitations of these studies are the small number of patients included, the high variability of conservation protocols and the absence of plasma data, which does not allow for research on the correlation between clot composition and plasma biomarkers.",[317,318,29,319,320],"Stroke, Acute","Biological Specimen Banks","Etiology","Prognosis","2026-01-16",{"date":323,"type":41},"2026-01-20",{"date":325,"type":41},"2017-07-13",{"date":327,"type":22},"2028-01-01",{"name":329,"class":330},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",12,{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":346,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":81},"100598450","evaluation-of-a-plasma-marker-p-tau217-for-the-biological-diagnosis-of-alzheimers-disease-and-comparison-with-csf-markers-100598450","NCT07071649","Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers","ALZBIOSANG","Inclusion Criteria:\n\n* All patients addressed to the memory center of CHU Amiens with a clinical suspicion of AD, for whom lumbar puncture \u002F CSF biomarkers of AD determination is proposed.\n\nExclusion Criteria:\n\n* Minor patients\n* pregnant women\n* patients under guardianship",{"count":5,"type":22},[25],"The biological diagnosis of AD is actually performed by analysing Aβ1-40 and Aβ1-42 peptides, total tau and tau phosphorylated at Thr181 (p-Tau181) from cerebrospinal fluid (CSF) samples obtained by lumbar puncture (LP). Phospho-Tau 217 (p-Tau217) is a new biomarker that could be measured in plasma. The aim of this study is to compare the performances of plasma p-Tau217 with those of the reference CSF biomarkers in 150 patients recruited in the memory center of CHU Amiens (France). The study will be conducted during 18 months. The inclusion will be proposed to all patients for whom an indication of lumbar puncture \u002F CSF is raised in a context of clinical suspicion of AD. During the daily hospitalization during which CSF will be collected for the \"classical\" biomarkers testing, a single tube of blood will be collected (anticoagulant EDTA, collected for p-Tau 217 analysis). The performances of CSF and plasma pTau 217 will be compared with the clinical diagnosis of AD (+, -, or indeterminate).",[343,29,344,345],"Alzheimer's Disease","Non-invasive Diagnosis","Phosphorylated Protein p-tau217",[343,29,347,348],"Non-invasive diagnosis","Phosphorylated protein p-tau217","2026-01-15",{"date":321,"type":41},{"date":352,"type":41},"2025-11-20",{"date":354,"type":22},"2027-02",{"name":137,"class":48},{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":146,"sex":18,"minAge":364,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":81},"100619489","clinical-aspects-management-and-surveillance-of-febrile-illnesses-in-drc-100619489","NCT07345286","Clinical Aspects, Management and Surveillance of Febrile Illnesses in DRC","Aspects Cliniques, Prise en Charge et Surveillance Des Maladies fébriles en RDC","FI-CARE","Inclusion Criteria:\n\n* Ongoing fever objectified at presentation, or documented at home or other health center within 24 hours prior to presentation, defined as: axillary or tympanic temperature \\> 37.5°C, or oral or rectal temperature \\> 38°C.\n* Opportunity for contact between patient (or designated relative) and study team on days 7, 14 and 21.\n* Informed consent to participate signed by the patient (adult) or a legally acceptable representative (child or patients whose condition does not allow them to sign informed consent), with the assent of children aged 12 and over, wherever possible.\n\nExclusion Criteria:\n\n* Child less than two months old.\n* Hospitalization of \\> 48h in the last 14 days.","2 Months",{"count":366,"type":22},500,"The epidemiology and outcome of febrile illnesses in the Democratic Republic of Congo (DRC) is poorly documented. The FIKI² study, a prospective observational study of community-acquired febrile illnesses coordinated by ITM and INRB and conducted at 2 clinical sites from 2021 to 2023, has deepened the knowledge of clinical presentation, etiology, outcome and profile of inflammatory\u002Finfectious biomarkers (white blood cells and C-reactive protein, or CRP).\n\nThe management of febrile illnesses remains fraught with clinical challenges. Overuse of antibiotics in primary care remains a reality in the field, and has been observed in several studies, including FIKI². A number of initiatives are underway to address this problem, such as the use of biomarkers, the development of treatment guidelines and electronic decision support systems. The FIKI² study highlighted the potential role of CRP in rationalizing antibiotic use. In parallel, the 'AWARE antibiotic book' was published at the end of 2022 by the WHO, providing recommendations on the choice (or otherwise) of antibiotic therapy for over 30 common clinical infections, in both primary care and hospital settings.\n\nBased on the results of the FIKI² study, the main aim of the FI-CARE study is to investigate the impact of these new tools (CRP biomarker, AWARE antibiotic book, and electronic decision support systems) on first-line antibiotic use. Secondly, the study will consolidate previous results from FIKI² sites in terms of monitoring the etiologies of community-acquired febrile illnesses (particularly arboviruses); and reinforce this monitoring at new sites (depending on opportunities). This complementary study will also pursue FIKI²'s strategic objectives of strengthening clinical research capacity and consolidating biobanks in the DRC.\n\nFI-CARE is a prospective, observational, multicenter cohort study of adults and children presenting to the emergency department or outpatient clinic with community-acquired febrile illness. A laboratory component with sample storage in a biobank is added in a modular fashion according to laboratory and research capacities, epidemiological interest and available funds.",[369,29,370],"Febrile Illness Acute","Surveillance",[372,373,69,374,375,376,377],"febrile illness","CRP","surveillance","clinical characteristics","Subsaharan Africa","malaria","2026-01-09",{"date":349,"type":41},{"date":381,"type":41},"2025-01-20",{"date":383,"type":22},"2027-01-01",{"name":385,"class":48},"Institute of Tropical Medicine, Belgium",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":146,"sex":18,"minAge":19,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":396,"conditions":397,"keywords":402,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":4},"100588191","comparison-of-aquaporin--4--5--9-and-il-8-levels-in-gcf-dentin-fluid-and-pulp-samples-100588191","NCT06938191","Comparison of Aquaporin -4, -5, -9 and IL-8 Levels in GCF, Dentin Fluid and Pulp Samples","Comparison of Aquaporin -4, -5, -9 and IL-8 Levels in Gingival Crevicular Fluid, Dentin Fluid and Pulp Samples of Healthy and Acute Irreversible Pulpitis Teeth","Inclusion Criteria:\n\n* Patients aged 18 to 64 years.\n* Patients without any known systemic disease.\n* Patients requiring root canal treatment for prosthetic purposes (Healthy pulp group).\n* Patients with third molars (wisdom teeth) indicated for extraction due to orthodontic or other clinical reasons (Healthy pulp group).\n* Patients diagnosed with symptomatic irreversible pulpitis based on the criteria established by the American Association of Endodontists (AAE) (Symptomatic irreversible pulpitis group).\n* Patients scheduled for routine root canal treatment at the Department of Endodontics, Faculty of Dentistry, Kırıkkale University.\n* Patients who have provided written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with any known systemic disease.\n* Pregnant women or those suspected of being pregnant.\n* Patients who have used antibiotics, anti-inflammatory drugs, or antidepressants within the past 4 weeks.\n* Patients with significant dental plaque or calculus, gingival redness or bleeding, severe gingivitis, generalized periodontitis, or periodontal pockets deeper than 4 mm.\n* Patients with teeth showing internal or external root resorption.\n* Patients for whom complete rubber dam isolation cannot be achieved.\n* Patients with teeth exhibiting signs of necrosis, apical lesions, swelling, or presence of a sinus tract.\n* Patients with immature teeth presenting open apices.\n* Patients with third molars (wisdom teeth) that are not fully erupted or have been previously diagnosed with pericoronitis.","64 Years",{"count":395,"type":22},70,"This study aimed to compare the changes in AQP -4, -5, -9, and IL-8 levels in pulp tissue, GCF, and dentin fluid samples routinely obtained during the treatment of healthy and symptomatic teeth diagnosed with irreversible pulpitis and investigate whether there is a correlation between them.\n\nA total of 70 patients aged 18-64 years with healthy (Group 1) and symptomatic irreversible pulpitis (Group 2) diagnosed at Kırıkkale University, Faculty of Dentistry, Department of Endodontics who will undergo routine root canal treatment will be included in the study, with a minimum of 35 participants for each group. Before starting treatment, DOS samples will be taken from healthy, symptomatic, irreversible pulpitis-diagnosed teeth and teeth contralateral to these teeth. A dentin fluid sample will be taken by holding the membrane on the dentin surface, and the pulp tissue will be removed and transferred to Eppendorf tubes. The treatment process will be completed by applying routine root canal procedures to the teeth. The samples' Aquaporin -4, -5, -9, and IL-8 levels will be analyzed by specific enzyme-linked immunosorbent assay (ELISA).",[398,399,400,401,29],"Pulpitis","Pulpitis - Irreversible","Pulp Inflammation","Healthy Pulp",[403,404,405,406,407,408,409],"healthy pulp","pulpitis","irreversible pulpitis","aquaporin-4","IL-8","aquaporin-5","aquaporin-9","2025-11-27",{"date":412,"type":41},"2025-12-01",{"date":414,"type":22},"2025-12",{"date":416,"type":22},"2026-09-12",{"name":279,"class":48},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":18,"minAge":425,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":429,"conditions":430,"keywords":433,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":441,"locationsCount":81},"100537323","influence-of-timing-of-implant-placement-on-early-healing-molecular-events-100537323","NCT06276335","Influence of Timing of Implant Placement on Early Healing Molecular Events","Influence of Timing of Implant Placement on Early Healing Molecular Events: A Two-centre, Parallel Group, Pilot Study","Inclusion Criteria:\n\n* Age ≥25 years old\n* Good\u002Fcontrolled medical and psychological health\n* Good oral hygiene (FMPS≤20%)\n* Presence of a tooth in the aesthetic region (from incisor to second premolar) in need of extraction and further oral rehabilitation with a single dental implant.\n* For the IP group, the extraction socket should fulfil the following parameters, as described by the 5th ITI consensus \\[46\\]: intact socket wall; facial bone wall ≥1mm in thickness; no acute infection at the site; availability of bone apical and palatal to the socket to provide primary stability.\n* At least one neighbouring natural tooth.\n* A functional occlusion with a minimum of four occlusal units (i.e., pairs of occluding posterior teeth).\n* Willingness to read and sign a copy of the Informed Consent Form (ICF) after reading the Patient Information Sheet (PIS), and after the nature of the study has been fully explained and potential questions fully answered.\n\nExclusion Criteria:\n\n* Any known systemic disease severely affecting bone metabolism (e.g., Cushing's syndrome, Crohn's disease, rheumatoid arthritis, osteoporosis or diabetes type I and uncontrolled diabetes type II).\n* Self-reported HIV or viral hepatitis.\n* Self-reported alcoholism or chronic drug abuse.\n* Smokers (including current smokers or former smokers who had quit for \\\u003C 3 months); patients reporting use of vape\u002Fe-cigarettes will also be excluded.\n* Self-reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy and nursing, which can affect interpretation of study results).\n* Chronic treatment (i.e., 2 weeks or more) with any medication known to affect oral status or bone metabolism (e.g., bisphosphonates, hormone replacement therapy, immunosuppressants) within 1 month before baseline visit.\n* Chronic treatment with anticoagulants (including Aspirin), corticosteroids, immunosuppressants or other medications that may influence blood coagulation\u002Fcount.\n* Antibiotic or anti-inflammatory therapy during the month preceding the baseline exam.\n* Untreated caries lesions and untreated\u002Funcontrolled periodontal disease; If patients require periodontal treatment (non-surgical and\u002For surgical), this will be arranged outside the study protocol and completed prior to enrolment;\n* Inadequate keratinized tissue width (\\\u003C2 mm) in the mid-buccal aspect of the area to be treated in the study.\n* Physical handicaps that would interfere with the ability to perform adequate oral hygiene in the area of implant placement.\n* Patients requiring maxillary sinus lift surgery before implant placement.\n* Self-reported bruxism.\n* Patients not willing to receive animal-derived biomaterials for GBR.\n* Patients suffering from a known psychological disorder or with limited mental capacity or language skills such that study information could not be understood, informed consent could not be obtained, or simple instructions could not be followed.\n* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial.","25 Years",{"count":427,"type":22},24,[25],"Dental implants have been on the market for several years and they are routinely used to replace single\u002Fmultiple missing teeth with a high success rate. However, there is still a limited number of studies comparing the influence of timing of implant placement on wound healing. In addition, there is no data available on the signaling pathways and the expression of healing biomarkers involved in the early stages of osseointegration after immediate implant placement (IP) or delayed implant placement (DP).\n\nThe primary objective of this study is to describe changes in the expression of inflammatory, angiogenesis and osseous biomarkers of saliva at 1, 3, 7, 15 and 30 days and of PICF at 3, 7, 15 and 30 days after immediate implant placement (IP) compared with delayed placement (DP).",[431,432,29,123],"Dental Implant","Healing Wound",[434],"Implant placement protocol","2025-11-17",{"date":437,"type":41},"2025-11-19",{"date":439,"type":41},"2024-09-26",{"date":303,"type":22},{"name":442,"class":48},"Queen Mary University of London",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":18,"minAge":450,"maxAge":451,"enrollmentInfo":452,"targetDuration":453,"studyType":61,"phases":4,"briefSummary":454,"conditions":455,"keywords":456,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":81},"100606100","detection-of-disease-marker-factors-in-cyst-fluid-100606100","NCT07171151","Detection of Disease Marker Factors in Cyst Fluid","Measurement of MMP-8, MMP-9, RANKL, MIP-1alpha in Biopsy Samples From Odontogenic Cyst Patients","Inclusion Criteria:\n\n1. Individuals diagnosed with cysts\n2. Individuals who are not pregnant or breastfeeding\n3. Individuals who agree to sign the informed consent form\n\nExclusion Criteria:\n\n1. Systemically ill individuals who are contraindicated for surgery.\n2. Individuals who do not wish to sign the informed consent form.\n3. Individuals who are pregnant, breastfeeding, or using oral contraceptives will be excluded.","12 Years","80 Years",{"count":7,"type":22},"2 Weeks","The purpose of this observational study is to examine the cyst fluid obtained after a puncture procedure performed for cyst diagnosis in participants with cystic lesions on clinical and radiological examination.The main question it aims to answer is:\n\n\\- What is the exact mechanism of formation of odontogenic cysts?\n\nBiomarkers in the cyst fluid obtained after a puncture procedure performed as part of the diagnosis and treatment process of odontogenic cysts will be examined. The aim of this study is to gain insight into cyst pathology by examining the levels of biomarkers in odontogenic cyst fluid.",[29],[457,69,458,459],"odontogenic cysts","MMP-8","MIP-1alfa","2025-09-09",{"date":462,"type":41},"2025-09-12",{"date":464,"type":41},"2025-08-25",{"date":466,"type":22},"2026-05",{"name":468,"class":48},"Harran University",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":493},"100515219","combining-biomarkers-and-electronic-risk-scores-to-predict-aki-in-hospitalized-patients-100515219","NCT05988658","Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. E-STOP AKI 2.0 score in the top 10% of risk (historically from all hospitalized patients) within the last 12 hours. (First time across this 10% risk threshold during this hospital stay).\n3. Admitted to an inpatient ward, intermediate, or ICU care at the University of Chicago Medical Center (UCMC) or University of Wisconsin Health (UWHealth). (No Emergency Department patients)\n4. Patient or their legally authorized representative must be able to read, speak, and understand English, for the purposes of consenting. Otherwise, inclusion in this protocol will be done without regard to race, ethnic origin or gender\n\nExclusion Criteria:\n\n1. Voluntary refusal or missing written consent of the patient \u002F legal representative.\n2. Patients with a known history of end-stage renal disease on dialysis (including renal transplantation).\n3. Patients without a measured serum creatinine value during their inpatient stay.\n4. Patients with a creatinine \\>4.0 mg\u002Fdl at the time of admission or available in the EHR from the last 6 months\n5. Patients with prior episode of KDIGO defined AKI during this same hospitalization- regardless of E-STOP AKI 2.0 score\n6. Patients with prior renal consultation during their admission.\n7. Patient with an E-STOP AKI 2.0 above the top 10% risk threshold more than 12 hours ago during this same hospital stay.\n8. Incarcerated patients\n9. Pregnant patients",{"count":476,"type":22},800,"The study's objective is to evaluate the additive value of renal biomarkers (from blood and urine) for identifying individuals at high risk for severe acute kidney injury (AKI) above that of a novel natural language processing (NLP)-based AKI risk algorithm. The risk algorithm is based on electronic health records (EHR) data (labs, vitals, clinical notes, and test reports). Patients will enroll at the University of Chicago Medical Center and the University of Wisconsin Hospital, where the risk score will run in real time. The risk score will identify those patients with the highest risk for the future development of Stage 2 AKI and collect blood and urine for biomarker measurement over the subsequent 3 days.",[479,29],"Acute Kidney Injury",[479,29,481,482,483,484],"Renal Replacement Therapy","Artificial Intelligence","Risk Assessment","Clinical Nephrology","2025-09-05",{"date":462,"type":41},{"date":488,"type":41},"2024-01-05",{"date":490,"type":22},"2028-03-01",{"name":492,"class":48},"University of Chicago",2,{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":501,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":4},"100602971","the-relation-of-albuminglobulin-ratio-and-plateletalbumin-ratio-to-lupus-nephritis-100602971","NCT07130448","The Relation of Albumin\u002FGlobulin Ratio and Platelet\u002FAlbumin Ratio to Lupus Nephritis","The Relation of Albumin\u002FGlobulin Ratio and Platelet\u002FAlbumin Ratio to Lupus Nephritis in Upper Egypt ( Single Center Study)","Inclusion Criteria:\n\n* Patients aged 18 years or older diagnosed as SLE according to 2019 ACR\u002FEULAR classification criteria and with lupus nephritis (LN) according to the ACR criteria.\n* Patients with available baseline laboratory investigations and renal biopsy.\n\nExclusion Criteria:\n\n* Patients with chronic liver disease, hematological disorders, or malignancies affecting albumin\u002Fglobulin ratio or platelet counts.\n* Patients on nephrotoxic medications not related to SLE management.\n* Recent infections or acute inflammatory conditions.",{"count":502,"type":22},120,"Albumin\u002Fglobulin ratio and platelet\u002Falbumin ratio as a predictive non-invasive biomarker for lupus nephritis (LN) presence and severity",[505,506,29],"Lupus Nephritis (LN)","SLE - Systemic Lupus Erythematosus","2025-08-15",{"date":509,"type":41},"2025-08-19",{"date":511,"type":22},"2025-09",{"date":513,"type":22},"2026-10",{"name":515,"class":48},"Assiut University",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":18,"minAge":523,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":525,"conditions":526,"keywords":534,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":547,"locationsCount":81},"100467852","vanderbilt-memory-and-aging-project-100467852","NCT05372159","Vanderbilt Memory and Aging Project","VMAP","Inclusion Criteria:\n\n* Participants recruited will include 1,000 adults age 50 and older.\n* After the eligibility visit, a small portion of participants (\\~150) enrolling must meet diagnostic criteria for mild cognitive impairment according to a clinician diagnosis and\u002For medical records (i.e., participants must have mild memory or cognitive problems, but they must be free of any functional problems and not have Alzheimer's disease or another form of dementia). The remaining \\~850 participants will be cognitively unimpaired adults age 50 and older.\n* Because the neuropsychological tests used to measure cognitive performance are validated on English-speaking populations, we require that English be the primary language of all participants.\n\nExclusion Criteria:\n\n* No available reliable study partner\n* History of major psychiatric illness (e.g., schizophrenia, bipolar), neurological illness (e.g., stroke, epilepsy, multiple sclerosis, Parkinson's disease, dementia), or head injury with significant loss of consciousness. These exclusion criteria have been applied because they affect brain structure and function.\n* Diagnosis of congestive heart failure\n* Diagnosis of atrial fibrillation or other heart arrhythmia\n* Diagnosis of Chronic obstructive pulmonary disease\n* Diagnosis of cancer (current)\n* History of serious alcohol or drug abuse (past or current)\n* Participants unable to undergo MRI will be excluded. Reasons may include: a. Subjects who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.). b. Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced. c. Subjects who have cerebral aneurysm clips. d. Subjects who may have shrapnel imbedded in their bodies (e.g., from war wounds), metal workers and machinists (e.g., potential for metallic fragments in or near the eyes). e. Subjects who are pregnant. Given that the minimum age of recruitment for the current study is 50 years of age, it is unlikely that prospective participants will be excluded because of pregnancy. f. Subjects who have excessive amounts of metal dental work based on records released by their dentist.","60 Years",{"count":217,"type":22},"This study will use an observational cohort to cross-sectionally and longitudinally relate vascular health to clinical, imaging, and biological markers of early Alzheimer's disease and cerebrovascular disease among aging adults. Adjusting for relevant clinical covariates, we will test the hypothesis that vascular health is associated with clinical, brain magnetic resonance imaging (MRI), neuropsychological, and cerebrospinal fluid markers of early cerebrovascular and Alzheimer's disease changes (i.e., prior to the onset of significant cognitive decline or dementia). Secondarily, we will examine medical and genetic factors that might mediate associations between vascular health and brain aging, such as inflammatory processes, insulin resistance, and genetic factors (e.g., APOE, a susceptibility risk factor for dementia). Findings will advance knowledge regarding the role that vascular health plays in brain aging.",[527,528,529,29,530,531,532,533],"Alzheimer Disease","Aging","Aged, 80 and Over","Brain","Case-Control Studies","Cognitive Dysfunction","Neuropsychological Tests",[535,69,536,537,538,539,540],"Alzheimer's disease","brain MRI","cardiac MRI","mild cognitive impairment","vascular risk factors","longitudinal studies","2025-08-01",{"date":543,"type":41},"2025-08-06",{"date":545,"type":41},"2012-09-17",{"date":303,"type":22},{"name":548,"class":48},"Vanderbilt University Medical Center",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":556,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":559,"briefSummary":561,"conditions":562,"keywords":566,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":4},"100600710","early-phase-1-effect-of-bio-c-temp-versus-calcium-ydroxide-as-intracanal-dressings-on-postoperative-pain-intensity-and-periapical-mmp-9-level-in-patients-with-necrotic-pulp-100600710","NCT07101029","Effect of Bio-C Temp Versus Calcium Ydroxide as Intracanal Dressings on Postoperative Pain Intensity and Periapical MMP-9 Level in Patients With Necrotic Pulp","Effect of Bio-C Temp Versus Calcium Hydroxide as an Intracanal Dressing on Postoperative Pain Intensity and Periapical MMP-9 Level in Patients With Necrotic Pulp: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age between 18-50 years old.\n2. Males and females.\n3. Healthy patients categorized as I or II according to The American Society of Anesthesiologists.\n\n   (ASA I or II), with no underlying allergies.\n4. Single-rooted mandibular premolar teeth, having single root canal:\n\n   * Diagnosed clinically with pulp necrosis.\n   * Absence of spontaneous pulpal pain.\n   * Slight widening in the periodontal membrane space or with periapical radiolucency not exceeding 2\\*2 mm radiographically.\n5. Patients accepting to participate in the trial.\n6. Patients who can understand pain scale and can sign the informed consent\n\nExclusion Criteria:\n\n1. Medically compromised patients having significant systemic disorders (ASA III or IV).\n2. Pregnant females.\n3. If analgesics or antibiotics have been administrated by the patient during the past 24 hours preoperatively as it might alter their pain perception.\n4. Teeth with multiple canals. 9\n5. Teeth that show association with acute periapical abscess, swelling or fistulous tract.\n6. Teeth with vital pulp.\n7. Non-restorable teeth or teeth that could not be adequately isolated with a rubber dam.\n8. Immature teeth.\n9. Teeth with greater than grade I mobility or pocket depth greater than 4 mm.\n10. Teeth showing radiographic evidence of external or internal root resorption, vertical root fracture, perforation or calcification.\n11. Patients with two or more adjacent teeth requiring endodontic treatment.\n12. Patients reporting bruxism, clenching or TMJ problems.\n13. Inability to perceive the given instructions.","50 Years",{"count":558,"type":22},30,[560],"EARLY_PHASE1","To compare the effect of Bio-C Temp Bioceramic intracanal dressing versus calcium hydroxide as intracanal medicaments on:\n\n* Intensity of postoperative pain\n* levels of MMP -9 in Periapical Fluids.",[563,262,564,29,565],"Intracanal Dressing","Calcium Hydroxide","Inflammatory Mediators",[567,564,568,569,29,570],"Bio-C Temp","Intracanal medicament","Matrix Metalloproteinase 9","Post operative pain","2025-07-28",{"date":573,"type":41},"2025-08-03",{"date":575,"type":22},"2025-08",{"date":104,"type":22},{"name":578,"class":48},"Cairo University",{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":29,"eligibilityCriteria":585,"healthyVolunteers":146,"sex":18,"minAge":19,"maxAge":425,"enrollmentInfo":586,"targetDuration":4,"studyType":23,"phases":588,"briefSummary":589,"conditions":590,"keywords":594,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":4},"100600090","comparison-of-the-effects-of-aerobic-anaerobic-exercises-on-hormonal-and-immune-biomarkers-100600090","NCT07092969","Comparison of the Effects of Aerobic-Anaerobic Exercises on Hormonal and Immune Biomarkers","Comparison of the Effects of Aerobic and Anaerobic Exercises on Hormonal and Immune Biomarkers Measured by Blood and Saliva in Young Individuals","Inclusion Criteria:\n\n* Being a university student,\n* Being between the ages of 18 and 25.\n\nExclusion Criteria:\n\n* Having orthopedic problems that prevent exercise,\n* Having cognitive or mental health problems that prevent participation in exercise,\n* Having chronic systemic diseases such as cardiac, pulmonary, or nephrological.",{"count":587,"type":22},90,[25],"This study aims to compare the effects of aerobic and anaerobic exercise on hormonal, immunological, and metabolic biomarkers in young individuals using blood and saliva samples. It will also assess participants' physical activity levels, depression levels, and general lifestyle habits to explore their relationship with biomarker profiles. Biomarkers such as testosterone, progesterone, cortisol, IgA, alpha-amylase, insulin, lactate, and various inflammatory cytokines will be measured using ELISA. The study seeks to evaluate the physiological and psychosocial effects of different types of exercise in a holistic manner.",[591,29,592,593],"Activity, Motor","Exercise","Immunity",[595,596,597,598],"Exercise physiology","Aerobic and anaerobic exercis","Hormonal and immunological responses","Physical activity",{"date":600,"type":41},"2025-07-30",{"date":602,"type":22},"2025-09-15",{"date":43,"type":22},{"name":605,"class":48},"Sakarya Applied Sciences University",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":146,"sex":18,"minAge":556,"maxAge":613,"enrollmentInfo":614,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":616,"conditions":617,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":81},"100492856","exploring-the-predicting-biomarkers-from-mild-cognitive-impairment-to-dementia-ebmid-100492856","NCT05697588","Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)","Studies on Biomarkers for Mild Cognitive Impairment Conversion to Dementia","Inclusion Criteria:\n\n* Male or female patients aged ≥50 and ≤85 years;\n\n  * Meet the diagnostic criteria for dementia or MCI; ③ Neuropsychological score: MMSE 15-28 points, CDR≤1 point; ④ The patients and their families were informed and signed the informed consent.\n\nExclusion Criteria:\n\n* There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.);\n\n  * There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);\n\n    * Suffering from a disease that cannot cooperate with the completion of cognitive examination; ④ There are contraindications to nuclear magnetic resonance;\n\n      * There is mental and neurodevelopmental delay; ⑥ refuse to draw blood; ⑦ Refuse to sign the informed consent.","85 Years",{"count":615,"type":22},900,"Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.",[29,618],"MCI Conversion to Dementia","2025-07-18",{"date":621,"type":41},"2025-07-24",{"date":623,"type":41},"2023-02-28",{"date":625,"type":22},"2028-02-28",{"name":627,"class":48},"Cuibai Wei，Clinical Professor",{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":146,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":637,"conditions":638,"keywords":642,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":81},"100590140","il-40-and-il-41-levels-in-sepsis-septic-shock-and-healthy-individuals-100590140","NCT06963541","IL-40 and IL-41 Levels in Sepsis, Septic Shock, and Healthy Individuals","Comparison of IL-40 and IL-41 Levels in Patients With Sepsis and Septic Shock to Healthy Individuals","Inclusion Criteria:\n\n* Patient Group:\n\nClinical diagnosis of sepsis or septic shock, based on validated diagnostic criteria (e.g., Sepsis-3)\n\nAge 18 years or older\n\nAbility and willingness to provide a blood sample prior to initiation of antibiotic treatment\n\nHealthy Control Group:\n\nDetermined to be in good general health based on physical examination and medical history\n\nAge 18 years or older\n\nWillingness to provide written informed consent\n\nExclusion Criteria:\n\n* Patient Group:\n\nHistory of chronic inflammatory diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus)\n\nActive cancer or current use of immunosuppressive therapy\n\nPregnant or breastfeeding\n\nPresence of other serious conditions that may interfere with diagnosis or treatment (e.g., liver failure, chronic kidney disease)\n\nHealthy Control Group:\n\nRecent infection within the past month or use of antibiotics in the last 6 weeks\n\nHistory of chronic inflammatory diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus)\n\nUnderwent surgery within the past 6 months\n\nConditions that may affect blood parameters, such as recent blood donation or intense physical activity\n\nPregnant or breastfeeding",{"count":636,"type":22},80,"This study aims to investigate the blood levels of two recently identified immune-related proteins, Interleukin-40 (IL-40) and Interleukin-41 (IL-41), in patients with sepsis and its more severe form, septic shock. Sepsis is a serious condition caused by an abnormal immune response to infection, which can lead to organ dysfunction. Septic shock represents an advanced stage of sepsis, characterized by significantly higher mortality risk.\n\nIL-40 and IL-41 are newly discovered molecules that are thought to play important roles in the immune system. In this study, the blood concentrations of IL-40 and IL-41 in patients diagnosed with sepsis or septic shock will be measured and compared with those in healthy individuals. The findings may contribute to understanding whether these proteins can be used as biomarkers in the diagnosis or monitoring of treatment in sepsis-related conditions.",[639,640,641,29],"Sepsis","Septic Shock","Inflammation",[643,644,269,645,640,639],"IL-40","IL-41","Critical Illness","2025-04-30",{"date":648,"type":41},"2025-05-09",{"date":650,"type":22},"2025-05-15",{"date":652,"type":22},"2025-12-31",{"name":654,"class":48},"Melahat Yalcin Solak",{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":4,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":18,"minAge":662,"maxAge":663,"enrollmentInfo":664,"targetDuration":4,"studyType":23,"phases":665,"briefSummary":667,"conditions":668,"keywords":671,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":81},"100588673","phase-1-clinical-trial-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-mpd-1-in-patients-with-advanced-solid-tumor-100588673","NCT06944457","Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor","A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor","Inclusion Criteria:\n\n1. 19 to 75 years of age\n2. A histologically or cytologically confirmed, metastatic or unresectable advanced solid tumor patient who has used all available existing standard therapy but tumor progression is confirmed and further treatment tool is absent, or patient showing resistant or inadequate to standard therapy.\n3. KRAS mutation or PTEN loss is confirmed in tumor tissues prior to screening, and there is a documented record of this\n4. Patients without the history of administration of anthracycline drugs and\u002For anthracene\n5. Patients with at least one measurable or unmeasurable but assessable lesion in accordance with Response Evaluation Criteria in Solid Tumors Criteria (RECIST) 1.1\n6. In screening and C1D1, subjects with appropriate hematologic, kidney, and liver function confirmed by the following laboratory test (one more laboratory test is permitted during the screening period)\n\n\u003C!-- -->\n\n1. white blood cell (WBC) ≥ 3,500\u002Fmm3\n2. absolute neutrophil count (ANC) ≥ 1,500\u002Fmm3 (without CSF administration within 2 weeks prior to C1D1)\n3. platelets ≥ 100,000\u002Fmm3 (without transfusion within 2 weeks prior to C1D1)\n4. hemoglobin (Hb) ≥ 10 g\u002FdL (without transfusion within 2 weeks prior to C1D1)\n5. total bilirubin ≤ 1.5 times the normal upper limit (However, in case of Gilbert syndrome, this patient can participate in this clinical trial regardless of the results of total bilirubin\n6. aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 times the normal upper limit (five times of the normal upper limit in case of liver metastasis)\n7. albumin ≥ 2.5 g\u002FdL\n8. serum creatinine ≤ 1.5 times the normal upper limit\n9. INR ≤ 1.5 times the normal upper limit 7) Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 8) Patients with an expected survival period of more than 12 weeks 9) Patients who have recovered from previous therapy-related adverse event to Common Terminology Criterion for Adverse Events (CTCAE) version 5.0 grade 1 or below or to C1D1 levels (However, sHair loss (regardless of grade), subjects can be enrolled if they have with hair loss (regardless of grade) or peripheral neuropathy below grade 2 or laboratory test results show that they do not meet the exclusion criteria) can be enrolled.) 10) Patients, who after understanding all the relevant information of this clinical trial, decides to participate, and voluntarily signed a written agreement.\n\nExclusion Criteria:\n\n1. Within 4 weeks prior to the C1D1, subjects who underwent surgery, chemotherapy (cytotoxic, targeted antitumor drugs), immunotherapy, biological or hormonal therapy, or radiation therapy at areas exceeding 30% of bone marrow for the treatment of this clinical trial's target disease\n2. Participation in other interventional clinical trials (administration of investigational new drugs or use of investigational medical devices) within 4 weeks prior to C1D1\n3. Subjects who are identified with the following comorbidities during screening\n\n   \\- Clinically significant symptomatic or uncontrolled central nervous system metastasis (but can participate in this clinical trial if systemic corticosteroids have not been administered for more than 2 weeks prior to C1D1 and the condition is stable)\n   * Heart disease that could affect this clinical trial (left ventricular ejection fraction (LVEF) \\\u003C50%, congestive heart failure with New York Heart Association (NYHA) class II or higher, history of myocarditis, myocardial infarction or unstable angina within 24 weeks before C1D1, uncontrolled cardiac dysrhythmia by appropriate medication, coronary artery disease, etc.)\n   * History of thrombosis (e.g., thrombophlebitis, etc.)\n   * Uncontrolled hypertension (systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg)\n   * Clinically significant ascites\n   * Subjects who are infected with or carrying hepatitis B virus (HBV) or hepatitis C virus (HCV)\\* \\* When screening, serology tests show that any one of the following is positive: hepatitis B surface antigen (HBsAg), hepatitis B core antibody-immunoglobulin M (HBcAb-IgM), and hepatitis C virus antibody (HCV Ab) (However, if the HCV Ab test result is suspected to be false positive or positive due to past infection, HCV RNA test may be performed at each institution under the judgement of investigator and the HCV Ab and RNA test results are integrated to decide whether HCV is infected.)\n4. The following medical history is identified during screening\n\n   * Chickenpox or varicella zoster infection within 12 weeks prior to C1D1\n   * Uncontrolled active infectious diseases including known human immunodeficiency virus (HIV) positives\n5. Subjects with a history of administration of the following drugs during screening or C1D1\n\n   * Vaccination against yellow fever within 4 weeks prior to C1D1\n   * Penitoin within 1 week prior to C1D1\n   * G-CSF administration to correct absolute neutrophil count (ANC) levels within 2 weeks prior to C1D1\n\n     \\-- Transfusion of packed red cells or platelets to correct platelets or hemoglobin levels within 2 weeks prior to C1D1\n   * Trastuzumab within 28 weeks prior to C1D1\n6. Pregnant women, nursing mothers, and fertile women with plan for pregnancy\n7. Fertile women or men who do not agree to abstain from sex or perform effective contraception methods for at least 24 weeks after the end of administration\\* \\[\\* Effective Contraception\\]\n\n   * Hormone contraception (oral contraceptives, subcutaneous implants, etc.)\n\n     * Intrauterine device (IUD) or implantation of an intrauterine system (IUS) ③ Infertility procedures or surgeries (vasectomy, bilateral oviduct ligation\u002Fexcision, hysterectomy, etc.)\n\n       * Double contraception (concurrent use of contraceptive methods from ①\\~③ and condoms for men or women) ⑤ Absolute abstinence: Based on investigator's judgment, thorough abstinence from sex is approved if the subject's age, occupation, lifestyle, or sexual orientation guarantee contraception. However, periodic abstinence (menstrual cycle, mucus method, symptomatic body temperature method, etc.), resection, and withdrawal method (coitus interruptus) are not recognized as appropriate contraception methods.\n8. Subjects who have a history of allergies to doxorubicin or the excipient of MPD-1 or is suspicious of allergy\n9. Subjects in a state of prohibiting, limiting, or disrupting the assessments specified in the clinical trial (e.g., a history of alcohol or drug abuse within two years prior to C1D1)\n10. Subjects considered as unsuitable for participation in the clinical trial by the investigator (e.g., if the patient's health is unsuitable or participation in this clinical trial is not the best treatment for the patient)","19 Years","75 Years",{"count":427,"type":22},[666],"PHASE1","A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor",[669,670,29],"Cancer","Solid Tumor Cancer",[672,673],"PTEN Loss","KRAS mutation","2025-04-22",{"date":676,"type":41},"2025-04-25",{"date":678,"type":41},"2024-12-10",{"date":680,"type":22},"2027-06-30",{"name":682,"class":248},"Pharosgen Co.,Ltd",{"id":684,"slug":685,"hasResults":12,"nctId":686,"briefTitle":687,"officialTitle":688,"acronym":689,"eligibilityCriteria":690,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":691,"enrollmentInfo":692,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":694,"conditions":695,"keywords":700,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":706,"lastUpdatePostDateStruct":707,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":713,"locationsCount":81},"100530701","predictive-value-of-neurovascular-coupling-in-infants-with-congenital-heart-disease-100530701","NCT06190210","Predictive Value of Neurovascular Coupling in Infants With COngenital Heart Disease","The Impact of Perioperative Neurovascular Coupling on Outcome in Infants With Congenital Heart Disease.","NICO","Inclusion Criteria:\n\n* CHD warranting a first percutaneous or surgical intervention in the first 6 months, including but not limited to transposition of the great arteries (TGA), univentricular heart (UVH), Tetralogy of Fallot (TOF), coarctation of the aorta (CoA), total abnormal pulmonary venous drainage (TAPVU), Common arterial trunc (TA), large patent ductus arteriosus (PDA) or VSD and AVSD for which treatment is necessary within the first 6 months of life.\n* Treatment provided at the University Hospitals Leuven.\n\nExclusion Criteria:\n\n* Syndromes or proven genetic conditions which are associated with neurological impairment\n* CHD warranting treatment after 6 months of life\n* Suspected or proven metabolic diseases\n* No parental\u002Fguardian consent","6 Months",{"count":693,"type":22},200,"Infants with congenital heart disease (CHD) are at increased risk for delayed neurodevelopment. Multiple etiological explanations have been proposed, as there seems to be a multifactorial interplay of both prenatal and perioperative factors. The main goal of this research project is to focus on peri-operative physiological risk factors in infants with CHD which impair functional brain maturation or elicit brain injury, and subsequently creating a risk model and guidelines for standardized developmental follow-up in this population.\n\nPART 1: investigation of cerebral autoregulation and neurovascular coupling The homeostasis in cerebral blood supply regardless of perfusion pressure, is called Cerebral autoregulation (CAR). Neurovascular coupling (NVC) is the phenomenon in which blood supply increases as a result of increased brain activity in a specific area. At different times in the perioperative phase, these regulatory mechanisms will be estimated based on Electroencephalography (EEG) and Near Infrared Spectroscopy (NIRS), in addition to hemodynamic parameters.\n\nPART 2: cell-free DNA (cfDNA) extraction. Non-invasive monitoring of neuronal degeneration can be performed using cfDNA extraction techniques. Serial measurements of neuronal cfDNA will be used to determine whether and when this neuronal damage has occurred.\n\nPART 3: Prognosis and outcome. These risk factors, supplemented with demographic factors and medications administered, will be combined in an Artificial Intelligence-driven model, thus establishing a risk model for neurodevelopmental outcome. This model will be compared to the current standard-of-care, both structural imaging (ultrasound and MRI) and a clinical developmental assessment at 9 and 24 months of age (Bayley Scales of Infant Development-III).",[696,697,698,699,29],"Congenital Heart Disease","Neurodevelopmental Disorders","Electroencephalography","Near-Infrared Spectroscopy",[701,702,703,29,704,705],"Congenital heart disease","Neurodevelopment","Neuromonitoring","EEG","NIRS","2025-03-27",{"date":708,"type":41},"2025-04-02",{"date":710,"type":41},"2023-12-01",{"date":712,"type":22},"2027-09-30",{"name":714,"class":48},"Universitaire Ziekenhuizen KU Leuven",{"id":716,"slug":717,"hasResults":12,"nctId":718,"briefTitle":719,"officialTitle":720,"acronym":721,"eligibilityCriteria":722,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":613,"enrollmentInfo":723,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":725,"conditions":726,"keywords":732,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":747,"lastUpdatePostDateStruct":748,"startDateStruct":750,"completionDateStruct":752,"leadSponsor":754,"locationsCount":493},"100571207","genomic-and-methylation-markers-in-sclc-and-lcnec-for-chemo-immunotherapy-resistance-prediction-stratus-100571207","NCT06717243","Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)","A Prospective Observational Study on Genomic and Methylation Signatures in Patients with Extensive-Stage Small Cell Lung Cancer and Metastatic Large Cell Neuroendocrine Carcinoma Undergoing Chemo-Immunotherapy","STRATUS","Inclusion Criteria:\n\n* Age: Adults aged 18-85 years.\n* Histologically confirmed locally advanced extensive-stage small cell lung cancer (ES-SCLC).\n* Histologically confirmed locally advanced or metastatic large cell neuroendocrine carcinoma (LCNEC).\n* Treatment Plan: Eligible patients must be initiating standard-of-care chemo-immunotherapy, including platinum-based chemotherapy (cisplatin or carboplatin) combined with immune checkpoint inhibitors (atezolizumab or durvalumab).\n* Measurable Disease: At least one measurable or evaluable lesion as defined by RECIST 1.1 criteria.\n* Baseline Biospecimen Availability: Patients must agree to provide baseline blood and tumor biopsy samples for molecular and genomic analyses.\n* Treatment Naïve for Study Indication: Patients should not have received prior systemic therapy for ES-SCLC or LCNEC.\n* Life Expectancy: Estimated life expectancy of at least 3 months, as determined by the treating physician.\n* Follow-Up Commitment: Willingness to attend scheduled follow-up visits and provide additional biospecimens (blood and\u002For tissue) during treatment and at progression.\n* Performance Status: ECOG performance status of 0-2.\n* Organ Function: Adequate hematologic, renal, and hepatic function as per the treating physician's discretion.\n* Consent: Ability and willingness to provide written informed consent for participation in the study and collection of biospecimens (e.g., blood and tumor tissue).\n* Compliance with Study Protocol: Demonstrated ability and willingness to comply with all study-related procedures, including biospecimen collection and follow-up visits.\n* Non-Pregnant and Non-Lactating: Women of childbearing potential must have a negative pregnancy test at baseline and agree to use effective contraception during the study period.\n* Immunotherapy Eligibility: Patients must not have contraindications to immune checkpoint inhibitors (e.g., autoimmune diseases requiring systemic immunosuppressive therapy).\n* Platinum-Based Therapy Tolerance: Patients must be deemed medically fit to receive platinum-based chemotherapy (cisplatin or carboplatin) as determined by the treating physician.\n* No Active Infections: Patients must not have active, uncontrolled infections, including but not limited to tuberculosis, hepatitis B, hepatitis C, or HIV.\n* Psychosocial Stability: Patients must have adequate psychosocial support and the mental capacity to understand and provide informed consent for participation in the study.\n* Stable Brain Metastases: Patients with brain metastases are eligible if the metastases have been treated (e.g., surgery or radiotherapy) and are stable for at least 4 weeks prior to enrollment, as confirmed by imaging.\n* Steroid Use for Brain Metastases: Patients requiring corticosteroids for brain metastases are eligible only if they are on a stable or tapering dose equivalent to ≤10 mg\u002Fday of prednisone for at least 2 weeks prior to enrollment.\n\nExclusion Criteria:\n\n* Uncontrolled Brain Metastases: Patients with untreated or progressive brain metastases causing significant neurological symptoms.\n* Concurrent Malignancies: Presence of any active malignancy other than ES-SCLC or LCNEC within the past 3 years, except for treated non-melanoma skin cancer or in situ cervical carcinoma.\n* Previous Systemic Therapy: Prior systemic chemotherapy or immunotherapy for ES-SCLC or LCNEC.\n* Severe Comorbidities: Significant comorbidities, such as uncontrolled cardiovascular, respiratory, or autoimmune diseases, that could interfere with study participation or treatment.\n* Active Infection: Patients with active infections requiring systemic therapy, including tuberculosis, hepatitis B or C, or HIV.\n* Pregnancy or Lactation: Pregnant or lactating women, or women of childbearing potential who are not using effective contraception.\n* Immunosuppressive Therapy: Patients requiring systemic immunosuppressive therapy, including high-dose corticosteroids (equivalent to \\>10 mg\u002Fday prednisone), within 2 weeks prior to enrollment.\n* Severe Allergic Reactions: History of severe hypersensitivity reactions to any component of the planned treatment regimen, including platinum-based chemotherapy or immune checkpoint inhibitors.\n* Life-Threatening Conditions: Life expectancy less than 3 months, as assessed by the treating physician.\n* Inability to Comply: Patients unable or unwilling to adhere to study protocols, including biospecimen collection and follow-up visits.",{"count":724,"type":22},111,"The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine carcinoma (LCNEC). Both ES-SCLC and LCNEC are aggressive forms of lung cancer with limited treatment options and poor prognosis. While initial responses to chemo-immunotherapy are often promising, most patients develop resistance within a few months, resulting in disease progression and limited survival. This study seeks to explore the molecular and cellular changes that drive resistance, providing insights that could guide more personalized and effective treatment strategies in the future.\n\nThe study focuses on identifying genomic and methylation signatures, as well as analyzing circulating tumor cells (CTCs) and tumor DNA (ctDNA), to better understand the mechanisms of resistance. By collecting and analyzing these biomarkers over time, researchers aim to identify patterns that distinguish patients who benefit long-term from therapy from those who experience early resistance. These findings may pave the way for new diagnostic tools and therapies to predict and overcome resistance to chemo-immunotherapy.\n\nThe main questions this study seeks to answer are:\n\nAre there specific genomic or methylation patterns that predict resistance to chemo-immunotherapy in ES-SCLC and LCNEC? How are circulating tumor cells (CTCs) and tumor DNA (ctDNA) associated with disease progression, treatment response, and survival? What molecular differences exist between patients who respond long-term and those who develop resistance early in their treatment?\n\nParticipants will:\n\nProvide blood and tumor tissue samples before treatment to establish baseline molecular profiles.\n\nUndergo follow-up visits every 9 weeks during treatment, where additional blood samples and imaging tests will be collected to monitor disease progression and treatment response.\n\nOptionally provide tissue samples through re-biopsy if the disease progresses, enabling researchers to compare changes in tumor biology over time.\n\nAll blood and tissue samples will be de-identified and securely stored for genomic and epigenetic analyses. Blood samples will be examined for circulating tumor cells and tumor DNA, while tumor tissue samples will undergo in-depth genomic and methylation profiling. Researchers will use advanced molecular and bioinformatics techniques to uncover specific patterns associated with resistance, aiming to improve current treatment strategies and develop more precise therapies.\n\nThe study will analyze data from patients over three years, encompassing various stages of treatment and disease progression. By examining longitudinal samples, the study aims to capture the dynamic changes that occur in the tumor microenvironment and how these relate to treatment outcomes.\n\nThis research is particularly important because current treatment options for ES-SCLC and LCNEC are limited, and there are no established methods to predict which patients will respond to chemo-immunotherapy. Identifying biomarkers of resistance could transform clinical care, allowing oncologists to tailor treatments to individual patients' molecular profiles and improve survival outcomes.\n\nUltimately, the findings from this study could lead to the development of new biomarkers for resistance, improve early detection of treatment failure, and provide the foundation for novel therapies targeting resistant cancer cells. By addressing a critical gap in the understanding of resistance mechanisms, the STRATUS trial has the potential to significantly advance the field of personalized oncology.",[727,728,729,730,29,731],"Small Cell Lung Cancer","Large Cell Neuroendocrine (NE) Tumors","Treatment Failure","Biomarkers \u002F Blood","Immunotherapy",[733,734,735,736,737,738,739,740,125,741,742,743,744,745,746],"Small Cell Lung Cancer (SCLC)","Large Cell Neuroendocrine Carcinoma (LCNEC)","Chemo-Immunotherapy","Treatment Resistance","Circulating Tumor Cells (CTCs)","Circulating Tumor DNA (ctDNA)","Liquid Biopsy","Genomic Profiling","Biomarker Discovery","Lung Cancer","Molecular Signatures","Clonal Evolution","Personalized Oncology","Cancer Immunotherapy","2025-03-18",{"date":749,"type":41},"2025-03-19",{"date":751,"type":41},"2025-02-20",{"date":753,"type":22},"2028-12-01",{"name":755,"class":48},"Oncology Center of Biochemical Education And Research"]